ADMA Biologics Announces First Commercial Sales of ASCENIV™
see the press release
ADMA Biologics is a biopharmaceutical company relentlessly committed to creating superior products for immunodeficient patients at risk for infection. It is our devotion to this underserved population that fuels us, and our hands-on approach to production and development that sets us apart.
ADMA Biologics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Connection with Its Public Offering of Common Stock
ADMA Biologics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Connection with Its Public Offering of Common Stock:READ MOREADMA Biologics Receives BioNJ 2020 Innovator Award for ASCENIV™
ADMA Biologics Receives BioNJ 2020 Innovator Award for ASCENIV™:READ MOREADMA Biologics Announces Pricing of Upsized $82.3 Million Public Offering of Common Stock
ADMA Biologics Announces Pricing of Upsized $82.3 Million Public Offering of Common Stock:READ MORE